Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10451/51782
Título: | Comparative effectiveness of Tocilizumab and TNF inhibitors in Rheumatoid Arthritis patients: data from the Rheumatic Diseases Portuguese Register, Reuma.pt |
Autor: | Romão, Vasco C. Santos, Maria Polido Pereira, Joaquim Duarte, Cátia Nero, Patrícia Miguel, Cláudia Costa, José António Bernardes, Miguel Pimentel-Santos, Fernando M. Barcelos, Filipe Costa, Lúcia Melo Gomes, José António Pereira da Silva, José Alberto Branco, Jaime Cunha Canas da Silva, José Pereira da Silva, José António Fonseca, João Eurico Canhao, Helena |
Data: | 2015 |
Editora: | Hindawi |
Citação: | Biomed Res Int. 2015;2015:279890 |
Resumo: | Objectives: To compare the effectiveness of TNF inhibitors (TNFi) and tocilizumab in rheumatoid arthritis (RA) treatment, according to different response criteria. Methods: We included RA patients registered in the Rheumatic Diseases Portuguese Register treated with TNFi or tocilizumab for at least 6 months, between January 2008 and July 2013. We assessed remission/low disease activity (LDA) at 6 months according to DAS28, CDAI, and SDAI, as well as Boolean ACR/EULAR remission and EULAR response rate, adjusting for measured confounders. Results: Tocilizumab-treated patients (n = 95) presented higher baseline disease activity and were less frequently naïve to biologics compared to TNFi users (n = 429). Multivariate logistic regression analysis including the propensity score for receiving tocilizumab showed that patients treated with tocilizumab were more likely to achieve remission or LDA according to DAS28 (OR = 11.0/6.2, 95% CI 5.6-21.6/3.2-12.0), CDAI (OR = 2.8/2.6, 95% CI 1.2-6.5/1.3-5.5), or SDAI (OR = 3.6/2.5, 95% CI 1.5-8.7/1.1-5.5), as well as a good EULAR response (OR = 6.4, 95% CI 3.4-12.0). However, both groups did not differ in Boolean remission (OR = 1.9, 95% CI 0.8-4.8) or good/moderate EULAR response (OR = 1.8, 95% CI 0.8-4.5). Conclusions: Compared with TNFi, tocilizumab was associated with greater likelihood of achieving DAS28, CDAI, and SDAI remission/LDA and EULAR good response. Boolean remission and EULAR good/moderate response did not differ significantly between groups. |
Descrição: | Copyright © 2015 Vasco C. Romão et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Peer review: | yes |
URI: | http://hdl.handle.net/10451/51782 |
DOI: | 10.1155/2015/279890 |
ISSN: | 2314-6133 |
Versão do Editor: | https://www.hindawi.com/journals/bmri/ |
Aparece nas colecções: | IMM - Artigos em Revistas Internacionais FM-CUR-Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Comparative_Tocilizumab.pdf | 1,62 MB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.